VN October 2022

Vetnuus | October 2022 36 Immune-mediated keratitis (IMMK) is a corneal disorder that seems unique to the equine species. It is a relatively new and emerging disease category. It was first documented in 1995. A diagnosis of IMMK is made if there is a progressive or chronic (> 3 months duration), non-ulcerative or recurring corneal opacity with mild to moderate signs of cellular infiltrate, corneal vascularisation, and corneal oedema. IMMKs are also characterised by only mild ocular discomfort signs (mild epiphora, slight blepharospasm). Other characteristics include the absence of secondary uveitis, absence of microorganisms on culture, cytology or histopathology and clinical improvement with anti- inflammatory medications. Presumptive immunopathology The candidate pathogenesis of IMMK in horses is that the immune system has recognised an autoantigen in the cornea or a foreign protein, including microbial epitopes, within the cornea. An underlying infectious agent may thus be either the inciting or perpetuating cause (or both) in IMMK. The microorganism may be directly inciting active inflammation or may have induced immunologic cross-reaction with self-antigen in the cornea. Factors influencing the clinical expression of the immunoinflammatory response in cases of suspected IMMK are likely to include: • The nature of the antigen involved. This may be sequestered microbial or viral heteroantigens. • The dose and route of presentation of the putative antigen. • The immunophenotype of the patient. • The immune environment in the cornea at the time of antigen presentation. A primary clinical feature of IMMK is the absence of anterior uveitis, even in the presence of deep keratitis. This is likely to be a consequence of anterior chamber-associated immune deviation (ACAID) being maintained in the affected eye, protecting the intraocular structures of the anterior segment from involvement in the immunoinflammatory response. Four distinct disease entities are noted amongst the IMMK, and they are described as follows: Epithelial Immune-Mediated Keratitis (5% of cases) It is characterised by multifocal punctate areas in the ventral corneal epithelium. These lesions are not ulcerated but may have very faint surrounding cellular infiltrate. No corneal vascularisation and no signs of ocular discomfort are noted. Because of the geographic distribution of the corneal lesions, a viral agent (EHV 2 or 5) is frequently suspected in these cases. It is possible that retained, non-active viral epitopes within the cornea can stimulate a chronic immunologic response in all IMMKs. Much the same would be valid for other microbial agents, including fungal particles, which may act to trigger a low-grade auto- inflammatory response in the basal epithelial layer without precipitating frank ulcerative disease. Superficial Immune-Mediated Keratitis (45% of cases) Characterised by a non-painful, waxing and waning chronic corneal opacity. The opacity consists of a sub-epithelial superficial white to yellow stromal cellular infiltrate surrounded by superficial branching corneal vascularisation. These lesions are usually controlled by tapering doses of topical corticosteroids and long-term Tacrolimus. Midstromal Immune-Mediated Keratitis (27% of cases) Midstromal IMMKs have a similar clinical presentation to the superficial IMMK, except that the location of the vascularisation and cellular Dr Izak Venter, Digital Veterinary Ophthalmology Services (DVOS) Equine Immune- Mediated Keratitis [IMMK] Regulars I Ophthalmology Column Figure 1 Epithelial IMMK. There is a diffuse, central, superficial, non-vascularised corneal opacity, usually associated with minimal to no signs of discomfort. Figure 2 Superficial IMMK. The opacity consists of a subepithelial, superficial, white to yellow stromal cellular infiltrate surrounded by superficial, branching corneal vascularisation. Minimal signs of ocular discomfort are present.

RkJQdWJsaXNoZXIy OTc5MDU=